XNK Therapeutics logo
Svenska
Svenska
  • About
    About
    Close
    • Overview
    • Leadership Team
      CEO Quarterly Statement
    • Board of Directors
      Senior Advisors
  • Technology
    Technology
    Close
    • Autologous NK Cell Therapy Platform
    • GMP Facility
  • Project Portfolio
  • Collaborations
  • Newsroom
    Newsroom
    Close
    • Press releases
    • Calendar
  • Join Us
    Join Us
    Close
    • Vacant positions
  • Contact
  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Senior Advisors
    • CEO Quarterly Statement
  • Technology
    • Autologous NK Cell Therapy Platform
    • GMP Facility
  • Project Portfolio
  • Collaborations
  • Newsroom
    • Press releases
    • Calendar
  • Join Us
    • Vacant positions
  • Contact

Press releases

2017
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • All years
December 15, 2017

XNK Therapeutics receives orphan drug designation from EMA

For more info: https://news.cision.com/se/xnk-therapeutics-ab/r/svenska-cellterapikandidaten-cellprotect-har-erhallit-sarlakemedelsstatus-for-behandling-av-multipel,c2415694

January 31, 2017

XNK Therapeutics granted US patent for method to treat MM with NK cells

XNK Therapeutics AB (“XNK”) announced today it received a patent from the US for its method of treating multiple myeloma with expanded NK cells. “Being granted this patent in the US is an…

  • Newsroom
    • Press releases
    • Calendar

Subscribe

Read more about our protection of your personal data.

XNK Therapeutics AB

Hälsovägen 7, Novum
141 57 Huddinge
SWEDEN

Email: info@xnktherapeutics.com

© 2023 XNK Therapeutics

  • Cookies
  • Privacy Policy
  • Integritetspolicy avseende aktieägare